Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRE 515

Next Previous
Drug Profile

TRE 515

Alternative Names: DI-87; TRE-515

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles
  • Developer Harvard University; Stanford University; Trethera; University of California at Los Angeles
  • Class Anti-inflammatories; Antineoplastics; Diamines; Eye disorder therapies; Morpholines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Deoxycytidine Kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic neuritis; Acute disseminated encephalomyelitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Clinical Phase Unknown Amyotrophic lateral sclerosis
  • Preclinical Multiple sclerosis; Optic neuritis; Systemic lupus erythematosus
  • Research Crohn's disease

Most Recent Events

  • 03 Jun 2025 TRE 515 licensed to Trethera Corporation worldwide
  • 03 Jun 2025 Trethera Corporation has patent pending for TE 515 in major pharmaceutical markets including Europe, China and Japan
  • 03 Jun 2025 Clinical trials in Amyotrophic lateral sclerosis (PO) prior to June 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top